Biotechnology harnesses living cells to develop or modify products for targeted applications, including genetically modified foods. Closely tied to genetic engineering, it originated in the early 20th century within the agri-food sector and has since expanded into medicine and environmental fields. This growth has drawn significant interest from investors seeking high-potential opportunities.
Today, biotechnology's five key branches—human, environmental, industrial, animal, and plant—combat diseases and hunger, create safer products, minimize ecological impact, and optimize energy use.
These ventures rely on cutting-edge technologies developed by highly skilled experts with advanced academic and technical backgrounds. Here's a curated list of five standout biotech startups making waves:
Formed in 2018 by Pfizer and Bain Capital, Cerevel Therapeutics is a clinical-stage biopharmaceutical company focused on brain biology. It develops innovative therapies using advanced chemistry and pharmacology, prioritizing patient needs.
Many neurological disorders, such as epilepsy, schizophrenia, and Parkinson's disease, lack effective treatments. Cerevel aims to deliver precise therapies for these debilitating conditions.
Passage Bio is gaining traction for its focus on gene therapies targeting rare monogenic central nervous system (CNS) disorders. Patient needs drive every decision at this innovative firm.
The company develops AAV-delivered therapies to transform lives, builds partnerships with patient advocacy groups, advances lead candidates into clinical trials, and enhances proprietary manufacturing.
This U.S.-based startup accelerates small molecule drug discovery using AI. Kumuda identified a potent COVID-19 inhibitor that blocks the SARS-CoV-2 virus from entering human ACE2 receptors and targets neurological disorders.
Leveraging vast omics and chemical datasets, AI enables efficient target identification and lead molecule discovery, addressing unmet needs across various diseases.
10x Genomics is a leader in gene sequencing technology. Headquartered in the U.S., it recently secured funding valuing it in the billions after just seven years. Its tools power life sciences research with potential to reshape medicine.
The company designs, manufactures, and distributes sequencing solutions to research centers, biotechs, academics, and clinical organizations.
Launched in 2020, Curative leads in on-demand public health services, specializing in large-scale COVID-19 testing and vaccination across the U.S.
Partnering with communities, it delivers scalable infrastructure, accessible programs, and essential services. Led by CEO Fred Turner and a team of physicians, scientists, engineers, and experts, Curative operates over 13,000 sites in 18 states with three CLIA-certified labs.
